Table 2.
Comparison of Inpatient Management by Group
| Variable | Before propensity score matching |
After propensity score matching |
||||
|---|---|---|---|---|---|---|
| Early basal insulin group (n=86) | Delayed basal insulin group (n=79) | P value | Early basal insulin group (n=86) | Delayed basal insulin group (n=79) | P value | |
| Administration interval between CIII initiation and the first basal insulin, hr | 2.0±5.5 | 29.4±24.1 | <0.001a | 1.4±5.0 | 28.4±26.1 | <0.001a |
| Duration of CIII, hr | 36.4±29.7 | 30.3±24.3 | 0.136 | 35.3±31.0 | 29.9±26.6 | 0.270 |
| Glucose level immediately before CIII discontinuation, mg/dL | 177.1±40.9 | 168.9±45.9 | 0.296 | 175.2±39.6 | 168.2±44.0 | 0.391 |
| First dose of subcutaneous basal insulin, U | 16.6±5.6 | 16.7±8.1 | 0.660 | 16.4±5.7 | 18.6±8.9 | 0.137 |
| No. of blood glucose sampleb | 4.7±1.1 | 4.8±1.4 | 0.977 | 4.7±1.0 | 4.8±1.3 | 0.584 |
| Hypoglycemiac | 5 (5.8) | 4 (5.1) | 1.000 | 3 (5.6) | 2 (3.7) | 1.000 |
Values are expressed as mean±standard deviation or number (%).
CIII, continuous intravenous insulin infusion.
a
Values are statistically significant (P<0.05) by Mann-Whitney U tests;
b
During 24 hours after CIII discontinuation;
c
P value was calculated using a Fisher’s exact test.